Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

02 May 2003 : Original article  

PARP as disease target: endotoxic shock

P. Radermacher

Med Sci Monit 2003; 9(1): 58-0 :: ID: 15197

Abstract

The activation of PARP is attributed a crucial role in the development of multiple organ failure induced by endotoxemia, sepsis and septic shock, in particular as a result of compromised vascular contractility [1] and endothelial vasorelaxation [2], impaired mitochondrial respiration [3], and pulmonary as well as intestinal hyperpermeability [4]. Therefore, the therapeutic potential of PARP-inhibition has been investigated in endotoxic shock using nicotinamide, 3-aminobenzamide and phenantridinones. Nicotinamide, which was originally tested as a substrate supplement already 30 years ago [5], not only to is a (weak) PARP-inhibitor but also reduced NO [6, 7] and cytokine formation [8]. Results are controversial in vivo: while it stabilized hemodynamics, attenuated acute lung injury and ultimately improved survival in some studies [9,10], it failed to prevent lactic acidosis and renal or hepatic injury in others [11]. In our long term model of hyperdynamic porcine endotoxemia which is characterized by a sustained increase in cardiac output and thus mimicks the clinical scenario of human septic shock, nicotinamide did not have any beneficial effect on the endotoxin-induced metabolic disturbances [12]. 3-aminobenzamide, the ‘classical’ PARP-inhibitor used in endotoxic shock models, not only attenuated the LPS-induced vascular failure in vitro, but also reduced the pulmonary and intestinal microvascular injury and thus improved the mucosal barrier function [4, 13]. Nevertheless, in other models 3-aminobenzamide also failed to prevent visceral organ dysfunction [11], and in short term porcine endotoxemia it did not influence the LPS-induced effects on the systemic and pulmonary hemodynamics [14]. Most recently, the novel and highly PARP-1-selective phenanthridinones [15] were reported to prevent vascular failure and acute lung injury in rat endotoxic shock [16]. Moreover, used as a pretreatment, they preserved myocardial contractility both in endotoxin-injected rats [17] and porcine polymicrobial peritonitis [18]. Finally, in our endotoxmic swine model they improved stroke volume and blunted the otherwise progressive intestinal mucosal acidosis [19]. Taken together, nicotinamide showed controversial efficacy in the treatment of endotoxic shock, probably due to its relatively poor activity as a PARP-inhibitor and due to the potential hepatotoxicity when administered in high doses. By contrast, the currently available data study support the hypothesis that potent and selective PARP inhibitors may be of beneficial and therapeutic value in septic shock.

Keywords: endotoxin, Sepsis, nicotinamide, 3-aminobenzamide, phenanthridinone PARS inhibitors, rodent, Swine

Add Comment 0 Comments

Editorial

01 June 2024 : Editorial  

Editorial: Concerns as Highly Pathogenic Avian Influenza (HPAI) Virus of the H5N1 Subtype is Identified in Dairy Cows and Other Mammals

Dinah V. Parums

DOI: 10.12659/MSM.945315

Med Sci Monit 2024; 30:e945315

0:00

In Press

Clinical Research  

Epidemiology and Risk Factors for Revision Total Knee Arthroplasty in Chinese Patients: A Retrospective Stu...

Med Sci Monit In Press; DOI: 10.12659/MSM.943681  

Clinical Research  

Effects of the Cold Pressor Test on Popliteal Vein Diameter, Flow Velocity, and Blood Flow in the Lower Lim...

Med Sci Monit In Press; DOI: 10.12659/MSM.944560  

Clinical Research  

Outcomes of Anterior Lateral Approach and Gerdy's Tubercle Osteotomy for Tibial Plateau Fractures Involving...

Med Sci Monit In Press; DOI: 10.12659/MSM.943946  

Clinical Research  

Improving Function and Quality of Life in Patients with Chronic Neck Pain, Tension-Type Headache, and Forwa...

Med Sci Monit In Press; DOI: 10.12659/MSM.944315  

Most Viewed Current Articles

14 Dec 2022 : Clinical Research   1,494,766

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

17 Jan 2024 : Review article   1,476,009

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

16 May 2023 : Clinical Research   690,201

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Jan 2022 : Editorial   50,159

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750